TY - JOUR
T1 - The management of membranous nephropathy—an update
AU - Caravaca-Fontán, Fernando
AU - Fernández-Juárez, Gema M.
AU - Floege, Jürgen
AU - Goumenos, Dimitrios
AU - Kronbichler, Andreas
AU - Turkmen, Kultigin
AU - van Kooten, Cees
AU - Frangou, Eleni
AU - Stevens, Kate I.
AU - Segelmark, Mårten
AU - Tesar, Vladimir
AU - Anders, Hans Joachim
AU - Bruchfeld, Annette
AU - on behalf of the Immunonephrology Working Group, an official body of the European Renal Association
PY - 2022/6
Y1 - 2022/6
N2 - In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients.
AB - In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients.
KW - calcineurin inhibitors
KW - cyclophosphamide
KW - membranous nephropathy
KW - remission
KW - rituximab
U2 - 10.1093/ndt/gfab316
DO - 10.1093/ndt/gfab316
M3 - Article
C2 - 34748001
AN - SCOPUS:85131018498
VL - 37
SP - 1033
EP - 1042
JO - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
SN - 1460-2385
IS - 6
ER -